Using albumin modifications to identify early signs of chronic liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the use of albumin post-translational modifications as early biomarkers for chronic liver disease (CLD). By analyzing serum albumin isoforms, the researchers hypothesize that these modifications can indicate early hepatocellular damage and predict future liver disease progression. The study involves blood sampling from participants who meet specific criteria, including those with compensated fibrosis. The goal is to develop a non-invasive and sensitive diagnostic tool to improve early detection and management of liver diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 18 years old
* With a compensated fibrosis defined by an hepatic elasticity ≥10 kPa measured by FibroScan®
* Having had blood test at the hospital as part of a consultation or an hospitalisation at the inclusion including usual parameters for the liver disease follow-up
* Affiliated with or beneficiaries of a social security system
* Not opposed to participate to the study after being informed

Exclusion Criteria:

* Patients suffering from decompensated cirrhosis or with an history of decompensated cirrhosis
* Patients who received an albumin infusion in the month before the inclusion visit
* Patients suffering from stage 4 or 5 renal failure (GFR \< 29 ml/min/1,73m²)
* Patients suffering from cancer
* Pregnant or breastfeeding women or women of childbearing age without effective contraception (based on declaration)
* Patients suffering from impairment of mental faculties or a psychiatric disorder which could interfere with the understanding of the study

Where it's running

• Angers Univeristy Hospital
  Angers, France Recruiting
• Limoges University Hospital
  Limoges, France Recruiting
• Poitiers University Hospital
  Poitiers, France Recruiting
• Rennes University Hospital
  Rennes, France Recruiting
• Toulouse University Hospital
  Toulouse, France Recruiting
• Tours University Hospital
  Tours, France Not yet recruiting

Study contacts

• Study coordinator: Souleiman EL BALKHI, MD
• Email: Souleiman.ElBalkhi@chu-limoges.fr
• Phone: 0555058035

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Copper supplementation for people with cirrhosis

  This trial will try giving copper supplements to adults with cirrhosis who have low copper levels or signs of copper deficiency to see if liver-related health improves.

  Recruiting University of Washington · Seattle, Washington · NCT07471542

• Understanding how chronic liver disease patients with organ failure fare after non‑emergency hospital stays

  This study follows adults with chronic liver disease who are admitted to the hospital non-electively to see how their condition develops over six months when liver and/or other organs fail.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07270809

• Understanding social and health needs of people with chronic liver disease in outpatient care

  This project will see how common social needs are and whether adults with chronic liver disease want their outpatient providers to help with them.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07191886

• Using rifaximin to improve liver transplant outcomes

  This study is testing if taking the antibiotic rifaximin before and after liver transplant surgery can help prevent early problems with the new liver in adults.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06743464

• Endoscopic ultrasound shear wave elastography for measuring liver fibrosis

  This study will test whether endoscopic ultrasound shear wave elastography and attenuation imaging can estimate liver fibrosis compared with biopsy and FibroScan in adults with suspected MASLD or MASH.

  Recruiting at 3 sites Olympus Corporation of the Americas · Newport Beach, California and 2 other locations · NCT06592820

• Comparing intravenous and under-skin LAENNEC for alcoholic and non-alcoholic fatty liver disease

  This will test whether 10 ml intravenous LAENNEC given twice weekly for six weeks works better and is as safe as 4 ml subcutaneous LAENNEC in adults 19–70 with alcoholic or non‑alcoholic fatty liver disease.

  Recruiting Phase 3 Green Cross Wellbeing · Yongin-si · NCT06493799

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.